Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014

Login to access report north_east
Contact sales account_box

Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their incorporation into publically funded formularies, a situation that varies widely between countries in terms of the drugs and indications covered. As multiple marketed and late-stage emerging agents seek to optimize the market access opportunities offered by using biomarkers to target those patients most likely to benefit from drug therapy, this report assesses how the rising cost of personalized medicine is balanced with clinical need in breast cancer, non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and malignant melanoma.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…
north_east
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…
north_east
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east